Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

NCT00086099 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia
Acute Myeloid Leukemia

Interventions

DRUG: Idarubincin and Amufostine (Ethyol)
DRUG: Idarubincin

Sponsor

MedImmune LLC